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http://www.molecularneurodegeneration.com/content/9/1/26RESEARCH ARTICLE Open AccessGene expression changes consistent with
neuroAIDS and impaired working memory in
HIV-1 transgenic rats
Vez Repunte-Canonigo1, Celine Lefebvre3, Olivier George2, Tomoya Kawamura1, Marisela Morales4, George F Koob2,5,
Andrea Califano6, Eliezer Masliah7 and Pietro Paolo Sanna1*Abstract
Background: A thorough investigation of the neurobiology of HIV-induced neuronal dysfunction and its evolving
phenotype in the setting of viral suppression has been limited by the lack of validated small animal models to
probe the effects of concomitant low level expression of multiple HIV-1 products in disease-relevant cells in the
CNS.
Results: We report the results of gene expression profiling of the hippocampus of HIV-1 Tg rats, a rodent model
of HIV infection in which multiple HIV-1 proteins are expressed under the control of the viral LTR promoter in
disease-relevant cells including microglia and astrocytes. The Gene Set Enrichment Analysis (GSEA) algorithm was
used for pathway analysis. Gene expression changes observed are consistent with astrogliosis and microgliosis and
include evidence of inflammation and cell proliferation. Among the genes with increased expression in HIV-1 Tg
rats was the interferon stimulated gene 15 (ISG-15), which was previously shown to be increased in the
cerebrospinal fluid (CSF) of HIV patients and to correlate with neuropsychological impairment and neuropathology,
and prostaglandin D2 (PGD2) synthase (Ptgds), which has been associated with immune activation and the
induction of astrogliosis and microgliosis. GSEA-based pathway analysis highlighted a broad dysregulation of genes
involved in neuronal trophism and neurodegenerative disorders. Among the latter are genesets associated with
Huntington’s disease, Parkinson’s disease, mitochondrial, peroxisome function, and synaptic trophism and plasticity,
such as IGF, ErbB and netrin signaling and the PI3K signal transduction pathway, a mediator of neural plasticity
and of a vast array of trophic signals. Additionally, gene expression analyses also show altered lipid metabolism and
peroxisomes dysfunction. Supporting the functional significance of these gene expression alterations, HIV-1 Tg rats
showed working memory impairments in spontaneous alternation behavior in the T-Maze, a paradigm sensitive to
prefrontal cortex and hippocampal function.
Conclusions: Altogether, differentially regulated genes and pathway analysis identify specific pathways that can be
targeted therapeutically to increase trophic support, e.g. IGF, ErbB and netrin signaling, and reduce neuroinflammation,
e.g. PGD2 synthesis, which may be beneficial in the treatment of chronic forms of HIV-associated neurocognitive
disorders in the setting of viral suppression.* Correspondence: psanna@scripps.edu
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HIV-associated dementia, opportunistic infections and
neoplasms are significantly reduced since the introduc-
tion of combination antiretroviral therapy (cART) [1-4].
However, decreased HIV-associated dementia has been
associated with an increased prevalence of milder and
chronic forms of HIV-associated neurocognitive disor-
ders (HAND) and HIV-associated major depressive dis-
order along with increased life expectancy [4-10].
Release of HIV proteins and cytokine/chemokines
from monocytes/macrophages into the CNS parenchyma
plays a central role in HIV-associated neurological disor-
ders [11,12]. Several HIV-1 proteins also possess neuro-
toxic potential including gp41, Vpr, Nef, Rev and Vpu
[13-16]. Evidence suggests that the toxic actions of low
levels of HIV-1 products are key in the neuropathogen-
esis of persistent central nervous system HIV disease in
the setting of cART. In fact, after the introduction of
cART, HAND do not correlate with indicators of florid
HIV replication such as plasma viral load and low CD4+
counts [4], but are correlated with synaptodendritic in-
jury [17,18], which in experimental settings can be in-
duced by HIV-1 products even in the absence of virus
replication [19-21]. Therefore, there is a need to investi-
gate the pathologic consequences of the expression of
low levels of multiple HIV-1 proteins in disease relevant
cell types.
The HIV-1 transgenic (Tg) rats used in the present
study harbor a gag/pol-deleted HIV-1 provirus under
the LTR promoter [22], resulting in the co-expression of
multiple HIV-1 proteins in disease-relevant central ner-
vous system (CNS) cells such as microglia and astro-
cytes, but not in neurons [22,23]. Thus, the HIV-1 Tg
rats differ from most other non-replicating small animal
models expressing a single HIV-1 protein and from rep-
licating models [24]. The construct used in HIV-1 Tg
rats was previously used in mice where it was character-
ized by ectopic expression [25], possibly because of defi-
cient interaction of Tat with the murine cyclin T [26].
Despite lack of virus replication and production, HIV-1
Tg rats have a progressive clinical presentation leading
to a picture reminiscent of some of AIDS features later
in life that includes immunological abnormalities and
neurological manifestations [22,27].
Here we studied global gene expression in the hippo-
campus of HIV-1 Tg rats before the appearance of overt
symptomology to model the effects of concomitant ex-
pression of low levels of multiple HIV-1 products in the
CNS in the absence of viral replication, as seen in the
context of viral suppression in the setting of combin-
ation antiretroviral therapy (cART). Results show that
HIV-1 Tg rats have gene expression changes reminiscent
of neuroAIDS, significant astrogliosis and microgliosis,
and working memory impairments. We used the GeneSet Enrichment Analysis (GSEA) algorithm [28] to iden-
tify molecular pathways that are differentially activated
in HIV-1 Tg rats. We observed dysregulation of path-
ways associated with gliosis, consistent with the mor-
phological results in HIV-1 Tg rats, reduced trophic
support and synaptic plasticity, mitochondrial function,
as well as neurodegenerative diseases such as Hunting-
ton’s disease and Parkinson’s disease. HIV-1 Tg rats
showed working memory impairments in spontaneous
alternation behavior in the T-Maze, a paradigm sensitive
to prefrontal cortex and hippocampal function, support-
ing the functional significance of the gene expression
changes observed.
Results
Astrogliosis and microgliosis in HIV-1 Tg rats
Characterization of the neuropathological alterations in
the HIV-1 Tg rat was performed with antibodies against
the astroglial marker GFAP and the microglial cell
marker Iba1. Expression of HIV-1 proteins in the hippo-
campi of HIV-1 Tg rats was observed in both microglia
and astrocytes (Figure 1). As expected in the control ani-
mals, scattered astroglial cells were detected in the neo-
cortex and more active astroglia was observed in the
adjacent white matter and hippocampus (Figures 1 and 2).
In contrast, in HIV-1 Tg rats, levels of astrogliosis in the
neocortex and hippocampus were significantly increased
with the presence of enlarged astroglia with distended
cytoplasm (Figure 2A). Likewise, in control rats, moderate
numbers of microglial cells were detected in the neocortex
and hippocampus, in contrast in the HIV-1 Tg animals
there was an increase in Iba1 positive microglial cells
that was more prominent in the hippocampus than in
the neocortex (Figure 2C). These cells displayed abun-
dant branches and processes and the cytoplasm was
distended, suggesting the possibility of an activated
state. Significant astrogliosis and microgliosis were ob-
served by immunostaining in the hippocampi of HIV-1
Tg rats (Figure 2B, D). Quantitative reverse transcript-
ase polymerase chain reaction (RT-PCR) confirmed that
the expression of astrogliosis and microgliosis markers
was increased in the hippocampus of HIV-1 Tg rats
(Figure 3).
Gene expression changes in HIV-1 Tg rats
Gene expression was profiled in the hippocampi of
HIV-1 Tg and wild-type rats with high-density Affymetrix
arrays (Figures 4 and 5, Additional files 1 and 2: Tables S1
and S2). Pathway analysis with the GSEA algorithm [28]
revealed 23 pathways significantly differentially regulated
with statistical significance of p ≤ 0.01 (Figures 6 and 7,
Additional file 3: Table S3). Eight differentially regulated
pathways showed increased activation, while the rest was
decreased.
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Figure 1 Expression of HIV-1 products in HIV-1 Tg rats. A) HIV protein Tat was detected by immunohistochemistry with peroxydase
detection in the hippocampus in cells with microglia morphology (arrow) and B) by immunofluorescence with double labeling of HIV-1 Tat and
the microglia marker Ionized calcium binding adaptor molecule 1 (Iba-1) (arrow). C-F) Double immunofluorescence for HIV-1 gp120 (C-D) and for
the astrocytic marker glial fibrillary acidic protein (GFAP) (E-F) in the hippocampus of HIV-1 Tg rats revealed gp120-immunoreactive astrocytes
(arrow). The location of the field shown in C-F is indicated by the inset in C.
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entially expressed, several are consistent with astrocyte
and microglia activation and inflammatory processes
(Figures 2 and 3, Additional file 3: Table S3). In particu-
lar, pathways showing significant activation included 4
pathways indicative of DNA synthesis and cell prolifer-
ation, suggestive of astrocyte and microglia activation
(“REACTOME_SYNTHESIS_OF_DNA” and “REAC-
TOME_MITOTIC_G1_G1_S_PHASES”, “REACTOME_CD
T1_ASSOCIATION_WITH_THE_CDC6_ORC_ORIGIN_
COMPLEX” and “REACTOME_RNA_POL_I_TRANSCRIP-
TION_TERMINATION”, MSigDB geneset denomination;Figures 4 and 7, Additional file 3: Table S3). Two path-
ways indicative of interferon activation were also in-
creased (“REACTOME_INTERFERON_SIGNALING” and
“REACTOME_INTERFERON_ALPHA_BETA_SIGNALING”)
(Figures 5 and 6, Additional file 3: Table S3). Among the
interferon-related genes that were found to be increased
in HIV-1 Tg rats is the interferon stimulated gene 15
(ISG-15) (Figure 5, Additional file 1: Table S1). Other
inflammation- and astrogliosis-related genes increased in
the hippocampi of HIV-1 Tg rats include prostaglandin
D2 (PGD2) synthase (Ptgds) and procollagen type1-a2
(Col1A2) (Figure 5, Additional file 1: Tables 1).
Figure 2 Astrogliosis and microgliosis in the brain of HIV-1 Tg rats. A) Immunostaining for the astrocytic marker GFAP in HIV-1 Tg and control
rats. The panel to the left is a low power view (4X) of the neocortex and hippocampus, while the panels in the middle and right are at higher
magnification (400X) (B) Computer aided image analysis of the numbers of GFAP positive cells in the neocortex and hippocampus demonstrate a
significant increase in astroglial cells in the HIV-1 tg rats (Student’s t-test). C) Immunostaining for the microglial marker Iba-1 in HIV-1 Tg and control
rats. The panel to the left is a low power view (4X) of the neocortex and hippocampus, while the panels in the middle and right are at higher
magnification (400X); D) Computer aided image analysis of the numbers of Iba-1 positive cells in the neocortex and hippocampus demonstrate a
significant increase in astroglial cells in the HIV-1 Tg rats (* = p < 0.01; n = 6, by t-test). Bar = 250 and 25 μm at 4X and 400x, respectively.
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tion of intracellular signaling pathways relevant to trophic
support. In particular, the PI3K-mTOR signaling pathway
(“PID_MTOR_4PATHWAY”), the LKB1 pathway (“PID_
LKB1_PATHWAY”), and the integrin-linked kinase (ILK)
pathway (“PID_ILK_PATHWAY”), were downregulated
(Figures 6 and 7, Additional file 3: Table S3). Various down-
regulated genesets also contain numerous MAP kinases
(PID_MTOR_4PATHWAY;REACTOME_AXON_GUIDANCE;
PID_PRLSIGNALINGEVENTSPATHWAY; REACTOME_
L1CAM_INTERACTIONS; REACTOME_SIGNALING_BY_
ERBB2; REACTOME_DOWNREGULATION_OF_ERBB2_ERBB3_SIGNALING”, “PID_ILK_PATHWAY”), such
as ERK1 (MAPK3).
GSEA also showed downregulation of genesets related
to neuronal function and synaptic plasticity such as
“REACTOME_NEURONAL_SYSTEM” and “REACTO-
ME_AXON_GUIDANCE” (Figures 6 and 7, Additional
file 3: Table S3), which appears consistent with the re-
duced trophic tone suggested by the data.
GSEA pathway analysis also indicates that key roles in
the downregulation of transduction pathways mediating
trophic signals may be played by the insulin-like growth
factor (IGF), Erb-neuregulin-1 (NRG1) and netrin systems.
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Figure 3 RT-PCR validation of increased expression of astrogliosis and microgliosis markers in the hippocampus of HIV-1 Tg rats.
The mRNA for the astrocytic marker GFAP, and the microglia markers Iba-1 and CD11b (Mac1) were significantly increased in HIV-1 Tg rats over
controls, consistent with the immunohistochemistry results in Figure 2 (n = 6, **p < 0.01, ****p < 0.0001, by t-test).
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Igfbp6) and the IGF-activated gene T cell death-associated
gene 51 (TDAG51), also known as pleckstrin homology-
like domain family A member 1 (PHLDA), were differen-
tially regulated in HIV-1 Tg rats (Figure 5, Additional file 1:
Table S1) as was the IGF signaling pathways by GSEAFigure 4 Hierarchical clustering of top differentially expressed genes in
controls (Control). Gene expression was profiled in the hippocampi of HI
dendrogram shows 73 of the top 100 differentially expressed probesets t
Table S3). Genes are colored according to their expression values. Red ind
downregulated genes. Brightness is proportional to the extent of change(REACTOME_REGULATION_OF_INSULIN_LIKE_GROWTH_
FACTOR_IGF_ACTIVITY_BY_INSULIN_LIKE_GROWTH_
FACTOR_BINDING_PROTEINS_IGFBPS). GSEA also
showed differential regulation of Erb-neuregulin-NRG1 and
netrin signaling pathways (“REACTOME_SIGNALING_
BY_ERBB2”, “REACTOME_DOWNREGULATION_OF_the hippocampus of HIV-1 Tg rats (HIV) versus wild-type littermate
V-1 and wild-type rats with high-density Affymetrix microarrays. The
hat were found to be associated with gene names (Additional file 3:
icates upregulated genes in HIV-1 Tg rats, while blue indicates
in gene expression.
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Figure 5 RT-PCR validation of differentially expressed genes in the hippocampus of HIV-1 Tg rats. Examples of genes that were found to
be differentially regulated in the hippocamous of HIV-1 Tg rats include PGD2 synthase (Ptgds), interferon stimulated gene ISG-15 (ISG-15), IGF
binding protein 6 (Igfbp6) and the IGF-activated gene T cell death-associated gene 51 (TDAG51), Col1A2 (procollagen type1-a2), and the
mitochondrial protein ubiquitin domain containing 2 (Ubtd2). Lastly, among differentially expressed genes are Fbxw11 and Npm1, which interact
with HIV-1 proteins Vpu and Tat, respectively. Please see text (n = 6, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, by t-test).
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SIGNALING”; Figures 6 and 7, Additional file 3: Table S3).
Pathways related to neurodegeneration associated with
protein misfolding and mitochondrial dysfunction were
differentially regulated including “KEGG_PARKINSONS_
DISEASE” and “KEGG_HUNTINGTONS_DISEASE”.
Another significantly dysregulated pathway is the “REAC-
TOME_CALNEXIN_CALRETICULIN_CYCLE”, which in-
volves unfolded protein response genes.
Multiple genesets are indicative of dysregulation of
phospholipid metabolism (“EGG_GLYCEROPHOSPHOLI-
PID_METABOLISM”, “KEGG_GLYCEROLIPID_METAB-
OLISM” and “KEGG_PEROXISOME”; Figures 6 and 7,
Additional file 3: Table S3).
Lastly, two cellular targets of HIV-1 were differen-
tially regulated in the hippocampus of HIV-1 Tg rats,
Fbxw11 and the nuclear chaperone nucleophosmin/B23
encoded by the Npm1 gene (Figure 5 and Additional
file 1: Table S1).
Working memory impairments in HIV-1 Tg rats
To determine the functional correlates of the present gene
expression and pathologic findings, we then investigated
working memory in HIV-1 Tg rats using a hippocampus
and prefrontal cortex-dependent task [29-32]. Rats were
tested in the dark in spontaneous alternations in the
T-Maze, which is a paradigm sensitive to prefrontal cortex
and hippocampal impairments [29-32]. Visual cues were
not provided in the T-Maze paradigm, as done by others
[33], to minimize the influence of cataracts in HIV-1 Tgrats. HIV-1 Tg rats exhibited a marked decrease of alter-
nation behavior (SAB) compared to control rats (t10 = 4.2,
p < 0.01) (Figure 8A). Only the control rats alternated sig-
nificantly above chance (t6 = 7.1, p < 0.001) whereas HIV-1
Tg rats were not significantly different from chance level
(t4 = 1.2, p = ns). There was no difference between the two
groups in the latency to leave the start box or the latency
to make a choice (Figure 8B). Finally there was no differ-
ence between the two groups in the number of failed trials
or in the response bias (Control: 0.55 ± 0.02; HIV-1 Tg:
0.58 ± 0.04, p = ns). These results indicate an impairment
of hippocampal working memory in HIV-1 Tg rats that
was not a consequence of an increase of anxiety-related
behavior since we did not see increases in the latency to
leave the start box or in the number of failed trials in
HIV-1 Tg rats. Moreover this alteration of working mem-
ory is unlikely to come from an increase in the delay be-
tween the encoding and the recall of information or an
alteration of locomotor activity since the latency to start
and the latency to enter the arm were similar in both
groups. Thus, the gene expression changes observed
above are associated with neurocognitive impairments in
HIV-1 Tg rats.
Discussion
HIV-1 Tg rats as a model of neuroAIDS
A thorough neurobiological investigation of the neuro-
biology of HIV-induced neuronal dysfunction and its evol-
ving phenotype in the context of viral suppression has been
limited by the lack of validated small animal models to
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Figure 6 Top 23 differentially regulated pathways in the hippocampus of HIV-1 Tg rats and controls by GSEA. The Gene Set Enrichment
Analysis (GSEA) algorithm was used for pathway analysis using the MSigDB C2 canonical pathway collection [28]. Of the significantly differentially
regulated pathways with statistical significance of p≤ 0.01, 8 showed increased activation, while the rest was decreased. Among the increased
ones are pathways consistent with astrocyte and microglia activation, inflammatory processes, and interferon activation. Decreased pathways
indicate substantial downregulation of signaling systems involved in neuronal trophism and synaptic synaptic function. Pathways are colored
according to their expression values: red indicates upregulated genes in HIV-1 Tg rats, while blue indicates downregulated pathways. Brightness
is proportional to the extent of change in pathway expression.
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multiple HIV-1 products in disease-relevant cells in the
CNS. The HIV-1 Tg rats are constitutive, making them a
model of persistent exposure to viral proteins, although lack
of induciblity of the HIV-1 provirus can be seen as a limita-
tion. Here we show that HIV-1 Tg rats express viral proteins
in microglia and astrocytes, display astrogliosis and micro-
gliosis, and have gene expression changes consistent with
human neuroAIDS. Collectively, these results support that
HIV-1 Tg rats are a valid animal model of neuroAIDS.
Supporting the functional significance of the gene expres-
sion alterations reported here, HIV-1 Tg rats showed
working memory impairments in spontaneous alternation
behavior (SAB) in the T-Maze, a paradigm sensitive to pre-
frontal cortex and hippocampal function. Rats were testedin the dark in the T-Maze with no visual cues provided to
minimize the influence of cataracts in HIV-1 Tg rats, as
done by others [33]. In this regard it should be noted that
spontaneous alternation behavior (SAB) has been used in
aged rats with visual impairments [34] and to compare
anophthalmic mutant mice to wild-type controls [35]. It has
been previously shown that HIV transgenic rats exhibit im-
pairment in a spatial reversal learning task [36] without any
deficit in spatial memory or motor activity [37]. Our results
extend these studies by showing that HIV rats also exhibit
impairment in a working memory task. The deficits in the
reversal learning task and the working memory task may
both be explained by an impairment in the ability of HIV
rats to shift attention to a new target, a decreased working
memory capacity and/or an increase in perseveration.
Figure 7 GSEA plots of selected differentially regulated pathways. Representative differentially regulated pathways are shown including
pathways with increased and reduced activation in the hippocampus of HIV-1 Tg rats. Pathways with increased activation included pathways
indicative of (A) interferon activation; (B, C) cell division, consistent with astrogliosis and microgliosis; (D) peroxisome dysregulation. Pathways
with reduced activation (E-H) are indicative of reduced neuronal trophism and neurodegeneration.
Figure 8 Working memory impairment in HIV-1 Tg rats.
Working memory was significantly impaired in adult (4–5 months
old) HIV-1 Tg rats compared to wild-type controls (CONT) using the
spontaneous alternation behavior in the T-Maze, a paradigm sensitive
to prefrontal cortex and hippocampal impairments. A) HIV-1 Tg rats
exhibited a marked decrease of spontaneous alternation behavior
(SAB), a measure of working memory, compared to control rats
(n = 7 for both groups; t10 = 4.2, p < 0.01). Only the control rats
alternated significantly above chance (t6 = 7.1, p < 0.001) whereas
HIV-1 Tg rats were not significantly different from chance level
(t4 = 1.2, p = ns). There was no difference between the two groups
in the latency to leave the start box or the latency to make a choice
(B). ***p < 0.001 vs. chance; p < 0.01 vs. HIV-1 Tg rats.
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Gene expression and pathway analysis with the GSEA
algorithm show evidence of neuroinflammatory processes
and gliosis and synaptodendritic injury that together with
the impairment in working memory are reminiscent of
HAND in humans. In particular, the GSEA-based pathway
analysis that we employed suggests key dysregulation in
IFN regulated pathways, including ISG-15, which exerts
antiviral activities through members of the Endosomal
sorting complex required for transport (ESCRT) proteins
[38]. ISG-15 was proposed to be a predictive biomarker
for HAND [39,40]. In particular, ISG-15 was shown to
correlate with neuropathology and viral load and ISG-15
CSF levels may be predictive of future neurocognitive
impairments [38]. Several other inflammation-related
genes induced in the hippocampus of HIV-1 Tg rats were
previously associated with neuroAIDS in humans includ-
ing IGF binding proteins [41], prostaglandin D2 (PGD2)
synthase [42], and the pro-alpha2 chain of type I collagen,
Col1A2 [43]. Prostaglandins have been implicated in
inflammation-induced working memory deficits [44] and
imaging evidence supports that brain arachidonic acid
metabolism in HIV-1 transgenic rats is upregulated [45].
PGD2 has been implicated in the induction of astrogliosis
and demyelination [42,46] and has been associated with
immune activation, astrogliosis, microgliosis, and neu-
roAIDS in humans [42]. Col1A2 has been associated with
neuroAIDS in humans [43]. Collagen induction in the
CNS has been also observed in brain injury, Alzheimer’s
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plaques [47-49].
GSEA analysis showed downregulation of genesets
related to neuronal function, neuronal trophism, synaptic
plasticity, as well as genes and pathways associated with
degenerative diseases such as Huntington’s disease and
Parkinson’s disease, which include genes involved in pro-
tein misfolding and mitochondrial function. Decreased
expression of synaptic plasticity and axon guidance genes
was also observed in patients with HIVE in the The
National NeuroAIDS Tissue Consortium Brain Gene
Array [50] and in another study [43], consistent with the
notion that HAND in the cART setting correlates with
synaptodendritic injury [17,18]. Dysregulations of genes
related to Parkinson’s disease and Huntington’s disease
and mitochondrial function, is consistent with previous
studies suggesting mitochondrial dysfunction and oxida-
tive stress as potential contributors to HAND [51].
Signaling systems involved in neuronal trophism and
synaptic maturation and plasticity that were found to be
differentially regulated in HIV-1 Tg rats involve IGF,
ErbB and netrin, all of which have been shown to exert
trophic actions on dendritic spines [52-55], suggesting
that dysregulation of these pathways can contribute to
the synaptodendritic injury seen in neuroAIDS [17,18].
IGF signaling has been implicated in synaptic tro-
phism, depression and Parkinson’s disease [55-57]. GSEA
highlighted differential expression of IGF signaling genes
including increased Igfbp2 and Igfbp6 expression, which
were also found to be increased in the CSF of HIV-1
patients [41]. The IGFBPs have high affinities for the IGFs
[58,59] and their increased expression may result in
reduced trophic support as well as inflammatory processes
[60-62]. The IGF activated gene TDAG51/PHLDA1 [63],
which is expressed in both neurons and glial cells [64],
is implicated in insulin signaling [65] and has been
shown to have differential effects on susceptibility to
apoptosis [66-68].
ErbB2/B4 receptors and their ligand neuregulin-1
(NRG1) are encoded by candidate susceptibility genes for
schizophrenia [69]. Functional NRG1 receptors consist of
ErbB4 homodimers or heterodimers between ErbB2,
ErbB3 and ErbB4 since NRG1 binds ErbB3 and ErbB4,
and ErbB2 and ErbB4 have intrinsic tyrosine kinase activ-
ity [69]. Mice that lack the ErbBs with intrinsic tyrosine
kinase activity (ErbB2 and ErbB4) in the CNS have
reduced dendritic spine density and behavioral abnormal-
ities [53], possibly implicating this ErbB signaling in
synaptodendritic injury. Netrins are secreted mediators
that exert multiple trophic actions including axon guid-
ance [70], synaptic plasticity [71], prevention of apoptosis
[72,73], adult neurogenesis including in the course of CNS
regeneration [74-76], which is believed to be impaired in
neuroAIDS [77], and synaptic trophism [54].The GSEA analysis highlights a substantial downregu-
lation of intracellular signaling pathways relevant to
trophic support such as the PI3K-mTOR signaling path-
way, which mediates a vast array of trophic signals [78];
the LKB1 pathway, which is key to neuronal survival
following mitochondrial insults [79] and cross-talks with
the PI3K-mTOR pathway; and the ILK pathway, which
is involved in mediating trophic signals of the extracellu-
lar matrix and trophic factors as well as in the anti-
apoptotic effect of the PI3K pathway [80]. Recent studies
have indicated impaired processing and transport of
neurotrophic factors in HIV-1 neuropathogenesis [81-83].
The PI3K-mTOR signaling pathway is involved in synaptic
plasticity [84-86] and was shown to be dysregulated in the
frontal cortex of patients with neuroAIDS [43]. Downreg-
ulated genesets also contain numerous MAP kinases
including ERK1 (MAPK3), which was previously impli-
cated in the neurological actions of HIV-1 products [87].
The GSEA analysis also points to coordinated mito-
chondria and peroxisome dysregulations as well as dys-
regulation of phospholipid metabolism. Peroxisomes and
mitochondria exhibit a functional interplay in fatty acid
processing and intermediate metabolism [88,89]. It could
be envisioned that if peroxisomal metabolism is slowed,
critical metabolic intermediates (e.g., acetyl-CoA) may
not be adequately supplied to mitochondria and, con-
versely, disruption of mitochondrial metabolism can
similarly affect peroxisomal function. Peroxisome dys-
function may also contribute to increased lipid peroxida-
tion and cellular aging in HIV-1 [90,91]. In apparent
agreement with the dysregulation of these pathways, evi-
dence suggestive of altered phospholipid metabolism has
been reported in HIV-1 patients [92,93] and peroxisome
dysregulation can be indicative of altered brain oxidative
balance associated with HIV-1 [94].
Two cellular targets of HIV-1, Fbxw11 and nucleo-
phosmin/B23, were also differentially regulated in the
hippocampus of HIV-1 Tg rats. Fbxw11 is the gene coding
for βTrCP, a cellular ubiquitin ligase that was found to be
bound by the HIV-1 Vpu viral protein [95]. Nucleophos-
min/B23, encoded by the Npm1 gene, is a nuclear
chaperone implicated in the nuclear transport of Tat [96].
Potential therapeutic targets for neuroAIDS suggested by
gene expression analysis of HIV-1 Tg rats
Gene expression analysis can be a useful tool both to
gain insights in the pathogenesis and for the identifica-
tion of potential new therapeutic targets by identifying
the signaling pathways that have the potential to modify
the disease pathophysiology [97-99]. This is especially
needed in neuroAIDS as no targeted therapy other than
cART is currently recommended for the management of
HAND [100,101]. Adjunctive therapies for HAND ex-
plored to date include the low-affinity antagonist of the
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channel blocker nimodipine, and the monoamine oxi-
dase B inhibitor selegiline, in addition to antioxidants
and anti-inflammatory drugs such as minocycline. Mem-
antine and nimodipine are intended to protect from
excitotoxic neuronal damage associated with excessive
glutamate release [102,103]. Selegiline is a drug used for
the treatment of early-stage Parkinson’s disease, depres-
sion and dementia [104,105].
Our gene expression results showing decreased expres-
sion of Parkinson's disease-related genesets lend support
for the use of selegiline in HAND and potentially for other
therapeutics used in Parkinson's disease such as methyl-
phenidate, a stimulant that reduces reuptake of dopamine
and norepinephrine that has proven beneficial in lowering
fatigue scores in HIV patients [106]. The present results of
increased PGD2 synthase (Ptgds), is in keeping with previ-
ous studies that showed elevated PGD2 levels in HIV-1-
positive patients [42]. A potential role of prostaglandins in
HIV-1 neuropathogenesis is also indicated by increased
expression of the prostaglandin synthetic enzyme COX-2,
which is also a characteristic of other degenerative con-
ditions such as Alzheimer's disease and amyotrophic
lateral sclerosis [107,108]. Dysregulation of prostaglan-
din synthesis in HAND lends support to the use of inhibi-
tors of cyclooxygenase-2 (COX-2) as well as newer
compounds targeting the PGD2 receptor. In this regard, a
COX-2 inhibitor has shown promise in downregulating
immune activation and improving T cell function in
HIV-1 patients [109].
The present gene expression results as well as the pre-
vious literature also point to a role in HAND of several
signaling systems with the potential to provide trophic
support to synapses and reverse the synaptodendritic in-
jury associated with HAND [17,18]. Among them are
IGF, ErbB and netrin signaling and the PI3K-mTOR sig-
nal transduction pathway, which mediates trophic and
plastic actions of various signaling systems.
IGF-1 therapy has shown potential in models of both
Parkinson’s disease [110,111] and Alzheimer's disease
[112,113]. These effects are at least in part mediated by
recruitment of PI3K [111,114]. Additionally, chronic
treatment with IGF-1 was protective in vitro against
gp120-mediated neuronal damage and was synergistic
with erythropoietin (EPO), at least in part, through coopera-
tive activation of PI3K [115]. GLP-1 and GLP-1 analogs,
which activate partially overlapping signal transduction
pathways as insulin and IGF-1 [114], have also shown bene-
ficial effects in preclinical models of neurodegenerative dis-
orders [116-119]. There is currently great interest in
developing drugs to modulate NRG1–ErbB4 and netrin
signalling [120,121]. Netrin agonists may be potentially
beneficial in neuroAIDS both by exerting neurotrophic
actions and by reducing inflammation [120]. The PI3Kpathway is itself a potential target for reversal of the
synaptodendritic injury associated with HAND. However,
as PI3K appears to play a role in the regulation of the
HIV-1 LTR promoter and virus latency [122,123], activa-
tion of PI3K in the cells that harbor the provirus may in-
crease levels of expression of HIV-1 products, potentially
leading to detrimental effects on cognition.
Conclusions
The investigation of HIV-induced CNS dysfunction in
the context of viral suppression has been limited by the
lack of validated small animal models with low level ex-
pression of multiple HIV-1 proteins in disease-relevant
cells. Here we show that HIV-1 Tg rats express viral pro-
teins in microglia and astrocytes and display astrogliosis
and microgliosis and show gene expression changes that
are reminiscent of HIV-1 infection in humans. Differen-
tially regulated genes and pathway analysis also identify
specific pathways that can be targeted therapeutically to
increase trophic support and reduce neuroinflammation
that may be beneficial in the treatment of chronic forms
of HAND in the setting of cART.
Methods
Animals
HIV-1 Tg and wild-type rats 4–5 months of age (Harlan
Sprague–Dawley) were used for the study. For immuno-
histochemistry animals were perfused under deep isofluor-
ane anesthesia with 4% paraformaldehyde in phosphate
buffer; for microarray analyses, animals were sacrificed
under deep isofluorane anesthesia and hippocampi were
quickly removed and processed for RNA extraction.
Immunocytochemical analysis and image analysis
Brains were post-fixed in phosphate-buffered 4% para-
formaldehyde at 4°C for 48 hrs and sectioned in the
saggital plane at 40 μm with a Vibratome 2000 (Leica).
Briefly as previously described [124] saggital brain vibratome
sections from the non-Tg and HIV-1 Tg rats were incu-
bated overnight at 4°C with the rabbit polyclonal anti-
bodies against Tat (NIH AIDS reagent program; cat#
1974) or mouse monoclonal antibodies against the astro-
glial marker - glial fibrillary acidic protein (GFAP, Milli-
pore), or a monoclonal antibody against the microglial
marker Iba-1 (1:1000, Sigma-Aldrich, Saint Louis, MO).
Primary antibody incubation was followed by incubation
with secondary biotinylated IgG, then avidin-HRP and
diaminobenzidine (DAB) detection. All sections were
processed under the same standardized conditions. Immu-
nostained sections were imaged with a digital Olympus
microscope and assessment of levels of Tat, GFAP and
Iba-1 immunoreactivity was performed utilizing the
Image-Pro Plus program (Media Cybernetics, Silver
Spring, MD). For each case a total of three sections (10
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to estimate the average number of immunolabeled cells
per unit area (mm2) and the average intensity of the
immunostaining (corrected optical density). All slides
were processed simultaneously under the same conditions
and experiments were performed in triplicate to assess the
reproducibility of results. To determine the co-localization
between HIV-1 proteins and astroglial and microglial cells,
double-labeling experiments were performed, as previ-
ously described. For this purpose, vibratome sections were
immunolabeled with the rabbit polyclonal antibody against
human Tat or gp120 (NIH AIDS reagent program) and the
mouse monoclonal antibodies against GFAP (Millipore)
and Iba-1 (Wako). Double-immunocytochemical analysis
was performed utilizing the Tyramide Signal Amplifica-
tion™-Direct (Red) system (NEN Life Sciences, Boston,
MA) to detect Iba-1 or GFAP and fluorescein isothiocyan-
ate (FITC)-conjugated secondary antibodies (1:75, Vector)
to detect Tat or gp120. Sections were imaged with a laser
scanning confocal microscope BioRad Radiance 2000
(Hercules, CA) equipped with a Nikon E600FN Ellipse
microscope (Japan) and using a Nikon Plan Apo 60x oil
objective (NA 1.4; oil immersion). Statistical significance of
differences in the expression of GFAP and Iba-1 between
HIV-1 Tg rats and controls was determined by unpaired
Student’s t-test.
Gene expression profiling
Processing of Affymetrix microarrays was carried out as
previously described, according to manufacturer’s proce-
dures [125,126]. All analyses were performed with R statis-
tical software. We analyzed 11 samples (5 HIV-1 Tg rats; 6
controls) hybridized on Affymetrix Rat 230.2. One add-
itional HIV sample was removed as it showed lower quality
than the other samples. Differential expression was com-
puted with functions from the package limma and takes
into account sample phenotype and batch. False Discovery
Rates were computed by Benjamini & Hochberg method.
Differential expression between HIV-1 and control rats
identifies 614 and 4 probes differentially expressed at
p-value < 0.01 and FDR < 0.05, respectively.
Pathways for GSEA analysis were from the MSigDb
collection C2 that contains major pathway databases in-
cluding KEGG, REACTOME and PID (http://www.
broadinstitute.org/gsea/msigdb/index.jsp). We “human-
ized” the rat gene expression profiles by first selecting
one probe per gene (the one with the highest coefficient
of variation) and then kept the genes that had a unique
human homologous gene (according to the database
Homologene http://www.ncbi.nlm.nih.gov/homologene)
for pathway analysis. Pathway differential activity was
performed with GSEA using t-statistics obtained from
the limma test as the reference list and pathway mem-
bers as genesets; 24 pathways showed a p-value < 0.01.We report the pathways with the MSigDB terminology
in the text and figures.RT-PCR
RT-PCR was carried out as previously described
[125,127,128] with SYBR Green (BioRad) detection using
an iQ5 Real-Time PCR Detection System (BioRad,
Hercules, CA). The relative amounts of target mRNA
were determined by the ΔCt method using β-actin for
normalization [129]. Statistical significance of differences
between HIV-1 Tg rats and controls was determined by
unpaired Student’s t-test.Working memory
Rats were tested in the dark (<20 lux) during the noctur-
nal period using two identical T-Mazes constructed of
black Plexiglas with no visual cues provided to minimize
the influence of cataracts in HIV-1 Tg rats, as done by
others [33]. Rats were first habituated to the experi-
menters over 4 days (5 min/day) as described in [29]
and [30]. On test day, rats were allowed to alternate be-
tween the left and right goal arms of the T-maze in 15
trial sessions. Each session consisted of 1 forced trial
followed by 14 free choice trials. Once the rat entered a
particular goal arm (4 paws inside), a guillotine door was
lowered to block entry to the opposite arm. The door
was removed only after the rat returned to the start arm,
thus allowing a new alternation trial to be started. If the
rat did not enter one of the two arms after 120 seconds,
the rat was placed in the previously chosen arm and the
trial was considered as failed. If after 30 seconds the rat
did not spontaneously return to the start box, the ex-
perimenter manually positioned the rat in the start box
for the next trial. The spontaneous alternation behavior
(SAB) and the response bias were calculated with the
formula below where n = number of choices, na’ = num-
ber of non-alternation responses, ρR
2 = probability of a
right turn, ρL
2 = probability of a left turn [130]. The re-
sponse bias corresponds to the tendency of an animal to
favor one side over the other. The values of the response
bias vary from 0.5 (no bias or same number of left and
right choices) to 1.0 (full bias or exclusive left or right
choices). Because animals with high response bias auto-
matically exhibit low SAB that may be independent of
any cognitive deficits, calculation of SAB without inte-
grating the response bias may lead to wrong interpreta-
tions of the results by artificially producing low values
below chance level. The formula was established so that
a response bias of 0.5 (no bias) does not affect the calcu-
lation of SAB while a response of 1.0 (full bias) will
neutralize the value of SAB to chance level (50%). This
correction ensures that low levels of SAB are not due to
a non-specific effect of response bias toward one side of
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to make a choice were also recorded.
SAB ¼ 50 1þ
n− na
0
ρL
2 þ ρR2
 
n
0
@
1
A
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:
9=
;;
Response Bia ¼ ρL2 þ ρR2
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